^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GSK2636771

    i
    Other names: GSK2636771, GSK-2636771, GSK 2636771
    Company:
    GSK
    Drug class:
    PI3Kβ inhibitor
    Related drugs:
    1m
    EAY131-N: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    GSK2636771
    2ms
    EAY131-P: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Dec 2026
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    GSK2636771
    2ms
    NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (clinicaltrials.gov)
    P2, N=6452, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Gilotrif (afatinib) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • sunitinib • Kadcyla (ado-trastuzumab emtansine) • Balversa (erdafitinib) • Mektovi (binimetinib) • adavosertib (AZD1775) • Truqap (capivasertib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • sapanisertib (CB-228) • ipatasertib (RG7440) • taselisib (GDC-0032) • omipalisib (GSK2126458) • ulixertinib (BVD-523) • Erivedge (vismodegib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Paletan (pertuzumab biosimilar) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Pertuvia (pertuzumab biosimilar)
    3ms
    PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P. (PubMed, JCO Precis Oncol)
    Although the primary end point of OR was not met, GSK2636771 demonstrated modest single-agent activity among patients with relapsed/refractory cancer having PTEN mutation/deletion with PTEN expression or PTEN protein loss.
    Journal
    |
    PTEN (Phosphatase and tensin homolog) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    GSK2636771
    11ms
    Biomarker-Integrated Umbrella, Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=400, Completed, Yonsei University | Phase classification: P2 --> P=N/A
    Phase classification
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • GSK2636771
    11ms
    Biomarker-Integrated Umbrella, Advanced Gastric Cancer (clinicaltrials.gov)
    P2, N=400, Completed, Yonsei University | Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2024
    Trial completion • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • GSK2636771
    1year
    EAY131-P: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    GSK2636771
    1year
    EAY131-N: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    PTEN expression
    |
    GSK2636771
    almost2years
    Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    GSK2636771
    almost2years
    Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Nov 2023 --> Nov 2024
    Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    GSK2636771
    almost2years
    Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
    Trial completion date • Trial primary completion date
    |
    PTEN (Phosphatase and tensin homolog)
    |
    PTEN expression
    |
    GSK2636771
    2years
    Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study. (PubMed, J Clin Oncol)
    Although biomarker group did not show better survival than the control group, IHC-based screening and allocation of patients with AGC to the second-line treatment in an umbrella design were feasible for effective early screening of novel agents.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • PIK3CB (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta)
    |
    MSI-H/dMMR • HER-2 negative
    |
    Opdivo (nivolumab) • Gilotrif (afatinib) • paclitaxel • Cyramza (ramucirumab) • GSK2636771